ERBB2 and glioblastoma: Regarding GBM, published CAR T cell-based clinical trials have been focused on cell surface targets such as epidermal growth factor receptor vIII (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and IL-13 receptor α chain 2 (IL13Rα2)4,5.